In short
There is currently 1 ongoing clinical trial investigating new treatment approaches for myocarditis post infection. This trial is testing corticosteroid therapy to help reduce heart inflammation and improve heart function in patients with acute myocarditis.
Clinical trial locations
- Belgium
- Italy
- Slovenia
- Spain
Study on the Use of Methylprednisolone Sodium Succinate for Treating Patients with Acute Myocarditis and Mildly Reduced Heart Function
This trial is investigating whether corticosteroid treatment can help improve heart function in patients with acute myocarditis. Myocarditis is inflammation of the heart muscle that can affect the heart's ability to pump blood properly. The study is testing a medication called Solu-Medrone, which is a type of corticosteroid that helps reduce inflammation in the body.
Main inclusion criteria:
- Adults between 18 and 69 years old
- Heart function measurement (LVEF) less than 50% and heart size measurement (LV-EDD) less than 56 mm on heart ultrasound
- Elevated levels of troponin, a heart-related protein, at least three times higher than the normal upper limit
- Symptoms suggesting heart inflammation that started within 3 weeks before joining the study
- Must join the study within 5 days of hospital admission
- For participants aged 46 and older, heart artery disease must be ruled out using coronary angiogram
- Must provide signed informed consent
Main exclusion criteria:
- Patients with acute myocarditis in certain specific circumstances that make them unsuitable for the study
Focus and goal: The main goal of this study is to determine whether corticosteroid therapy can improve the heart's pumping ability in patients with acute myocarditis. Participants are randomly assigned to receive either Solu-Medrone treatment or a placebo (inactive treatment). The treatment is given as an injection into the bloodstream over several days. During the study, doctors will closely monitor heart function using echocardiograms (ultrasound of the heart) and other tests. The primary goal is to see if the heart's ejection fraction (LVEF) improves to 55% or higher, or increases by at least 10% after 5 days of treatment. Follow-up assessments occur at 6 months and 2 years to evaluate long-term effects on heart function and overall health, including cardiac magnetic resonance imaging and quality of life questionnaires.
Investigational drug: Corticosteroid therapy, specifically Solu-Medrone 125 mg (methylprednisolone sodium succinate) with sodium chloride, administered intravenously. Corticosteroids work by reducing inflammation and modulating the immune response in the heart muscle, which may help alleviate symptoms and improve heart function.
Summary
Currently, there is one active clinical trial available for patients with myocarditis following infection. This trial is being conducted across four European countries: Belgium, Italy, Slovenia, and Spain, providing multiple location options for potential participants.
The study focuses on corticosteroid therapy as a potential treatment approach, specifically testing whether this anti-inflammatory medication can help improve heart function in patients whose hearts have been weakened by myocarditis. The trial compares this treatment against standard care to determine if it offers additional benefits in restoring the heart's ability to pump blood effectively.
The study is designed to track both short-term improvements (within days) and long-term outcomes (up to 2 years), which will help doctors understand whether this treatment approach could become a valuable option for patients affected by this condition.
